![]() Immunai Immunai is a biotechnology company specializing in immune cell data analysis for drug development. | ![]() Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. | ![]() MetaStat MetaStat, Inc. develops and commercializes diagnostic tests for risk of cancer metastasis, companion diagnostics and anti-metastatic drugs. | |||||
Founding Date | Founding Date 2013 | Founding Date 2011 | Founding Date 2018 | Founding Date 2015 | Founding Date 2018 | Founding Date 1998 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Private | Type Private | Type Subsidiary | Type Public |
Tags | |||||||
Locations | Locations Cambridge, US HQ | Locations Fremont, US HQ West Wickham, GB | Locations South San Francisco, US HQ Bothell, US Seattle, US | Locations Austin, US HQ Hamilton, CA | Locations New York, US HQ Prague, CZ Ness Ziona, IL Tel Aviv, IL Zurich, CH | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more | Locations Boston, US HQ |
Employees | Employees 1302% increase | Employees 22344% decrease | Employees 188 | Employees 287% decrease | Employees 1873% increase | Employees 3,25622% increase | Employees 6 |
Valuation ($) | Valuation ($) 101.6 m | Valuation ($) 340.9 m | Valuation ($) 243.3 m | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) 20.6 k |
Financial | |||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $69.6m (FY, 2025) | Revenue (est.) $36k (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $2b (FY, 2022) | Revenue (est.) $23.3k (FY, 2018) |
Cost of goods | Cost of goods N/A | Cost of goods $53.9m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $410.1m (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $15.8m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $1.6b (FY, 2022) | Gross profit N/A |
Net income | Net income ($50.9m) (FY, 2022) | Net income ($81.3m) (FY, 2025) | Net income ($274.4m) (FY, 2025) | Net income N/A | Net income N/A | Net income ($610.3m) (FY, 2022) | Net income ($3.2m) (FY, 2018) |
Funding | |||||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 55m (almost 6 years ago) | Latest funding round $ 215m (over 4 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 103m | Total funding raised $ 75m | Total funding raised N/A | Total funding raised $ 55m | Total funding raised $ 295m | Total funding raised $ 164m | Total funding raised $ 350k |

Personalis is a biotechnology company that specializes in cancer genomics.
View company
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
View company
Triumvira Immunologics is an immunotherapy company.
View company
Immunai is a biotechnology company specializing in immune cell data analysis for drug development.
View company